Skip to main content

Welcome to a Grasp lesson

Create a free account to keep studying and create your own study path.

Lesson 14

ADHD Medications: Benefits, Risks, and Individualized Care

Recommended resources

Welcome back. The previous lesson compared parent-focused, school-based, and adult psychological support. Medication has a different role: it may reduce ADHD symptoms enough to make daily activities easier, but it does not teach a routine, remove a distracting environment, or replace support in those settings.

This lesson explains the main medication options, the benefits and adverse effects worth tracking, and why prescribing involves an individual trial rather than finding a universally “best” drug. The aim is to understand treatment decisions, not to make them without a clinician.


What medication is intended to change

A useful treatment question is not only “Is attention better?” but “Is the person better able to do something that was difficult?” For a pupil, that might mean starting and completing more classwork. For an adult, it might mean following through on tasks without losing track halfway through. Medication can reduce inattention, hyperactivity, or impulsivity; the relevant benefit depends on the difficulties the person actually has.

Stimulants are commonly used ADHD medicines. The main families are methylphenidate and amphetamine-based medicines, including lisdexamfetamine. They can begin acting relatively quickly, though their duration depends on the preparation and the person. Non-stimulants include atomoxetine and guanfacine, among other options. Some, particularly atomoxetine, may need several weeks at an appropriate dose before their full benefit can be judged.

The video below gives a brief comparison in the context of children’s treatment. Its broad categories are useful, but do not treat its generalizations about effect size or how long all non-stimulants take to work as predictions for an individual.

ADHD medication for kids: Stimulants vs. non-stimulants | Parenting Behavior

Watch “ADHD medication for kids: Stimulants vs. non-stimulants” from Understood for an introduction to how the two groups are used.

Start with stimulant options, where the host contrasts preparations and their duration. Continue with benefits and effects, focusing on why a trial must track both. In non-stimulant options, notice the reasons another medicine might be considered and the two groups described.

The chart makes the categories easier to keep apart. It is a map of drug groups, not a prescribing sequence: a medicine appearing on it does not mean it is appropriate for every age or routinely offered in every health system.

ADHD medication families: methylphenidate- and amphetamine-based stimulants, and non-stimulants including atomoxetine, viloxazine, guanfacine, and clonidine. The chart groups medicines; it does not rank them or show who should receive them.

Guidelines make the age distinction clearer. In the NICE guidance, methylphenidate is the first medication offered to children aged five and over and to young people when medication is appropriate. For adults, methylphenidate or lisdexamfetamine can be offered first. If a properly assessed trial gives insufficient benefit or unacceptable adverse effects, a clinician may consider another preparation or medicine. NICE includes atomoxetine as a later option for adults, and atomoxetine or guanfacine for children and young people in specified circumstances. Choices and approvals can differ across health systems.

Recommendations | Attention deficit hyperactivity disorder: diagnosis and management | Guidance | NICE

Read the NICE recommendations to see how age, benefit, and tolerability shape medication choice, rather than memorizing a list of drug names.

Under “Medication choice – children aged 5 years and over and young people,” read recommendations 1.7.7–1.7.10, from children’s choices. Under “Medication choice – adults,” read recommendations 1.7.11–1.7.15, from adult choices. Finally, under “Further medication choices,” read recommendation 1.7.17, beginning specialist cautions. Notice particularly that guanfacine for adults and clonidine for children are not routine NICE choices without specialist advice.

“First-line” describes a recommended starting option when medication is being considered. It does not mean that everyone with ADHD must take it. Nor does a medicine’s position later in a guideline mean it cannot help someone: the question is whether its likely benefits, risks, and practical fit make sense for that person.



Benefits must be weighed against adverse effects

Medication effects are not a single score. Someone might report better focus yet also have so little appetite that eating becomes difficult, or sleep poorly enough that the next day is harder. Conversely, a manageable adverse effect may be outweighed by a substantial improvement in daily functioning. The person taking the medicine and the prescriber need to consider both sides.

Stimulants can cause reduced appetite, difficulty sleeping, stomach discomfort, or changes in mood; they can also affect pulse and blood pressure. Their effect may wear off at an inconvenient time. A longer-acting preparation may cover more of a school or work day and avoid a dose there, while a shorter-acting preparation can offer different scheduling flexibility. Neither duration is inherently better for everyone. Because stimulants can be misused or passed to someone else, safe storage and the risk of diversion also belong in the discussion.

Non-stimulants have different risks, not no risks. Atomoxetine may cause nausea, appetite or sleep changes, dizziness, or other adverse effects that warrant review. Guanfacine can cause sleepiness, dizziness, or low blood pressure; fainting needs clinical attention. Side effects vary by medicine, so it matters which non-stimulant is being discussed rather than treating the category as interchangeable.

MedlinePlus provides a short patient-oriented account of why finding the right medicine and dose takes follow-up. Its adverse-effect list is a prompt for discussion, not a claim that every listed effect occurs with every medicine.

Medicines for ADHD: MedlinePlus Medical Encyclopedia

Read this MedlinePlus Medical Encyclopedia page for the practical meaning of an individualized medication trial and the kinds of effects to report.

In “TYPES OF MEDICINES,” begin at medicine types. Then read “FINDING THE RIGHT MEDICINE AND DOSAGE,” from finding a fit. In “SAFETY TIPS FOR MEDICINE,” read from effects to report; continue through the “MEDICINE TIPS FOR PARENTS” passage about not sharing or selling stimulant medicines.

An adverse effect should be reported rather than managed by independently changing a dose or stopping a medicine. New severe mood changes, unusual thoughts, fainting, or a concerning heartbeat call for prompt medical advice. Equally, a good response to medication does not confirm ADHD, and a poor response does not rule it out. Response tells a clinician something about that treatment trial, not the underlying diagnosis on its own.



Why prescribing is a monitored trial

Before starting medication, a clinician checks that treatment is still needed and reviews the person’s circumstances: current difficulties, other mental or physical conditions, existing medicines, and potential safety concerns. NICE also recommends recording height and weight, pulse and blood pressure, and assessing cardiovascular health. An electrocardiogram is not routinely required for everyone; particular findings or risks may call for further assessment.

Recommendations | Attention deficit hyperactivity disorder: diagnosis and management | Guidance | NICE

Return to the NICE guideline to connect an initial safety review with what clinicians measure while finding an effective dose.

In “Baseline assessment,” read recommendations 1.7.4–1.7.5, beginning baseline checks; pay attention to the sentence explaining when an ECG is not needed. In “Considerations when prescribing ADHD medication,” read recommendations 1.7.20–1.7.21, from preparation choices. Then, in “Dose titration,” read recommendations 1.7.26–1.7.28, from adjustment and review. Look for how the guideline defines an optimized dose using functioning as well as symptoms and tolerability.

Titration means adjusting treatment while checking what happens, rather than assuming the initial dose or preparation is the right one. Suppose a person can now begin a previously difficult task, but regularly loses sleep. That is useful information, not simply “success” or “failure.” A prescriber can review the timing, preparation, dose, or choice of medicine alongside the benefit. If another condition increases the risk of adverse effects, titration may need to be slower and monitoring more frequent.

Monitoring continues after a dose is settled. NICE recommends following effectiveness and adverse effects, checking pulse and blood pressure before and after dose changes and at intervals thereafter, and tracking weight—and children’s growth—over time. Sleep and changes in behaviour also matter. Follow-up is an opportunity to ask whether improvement is reaching everyday activities, not just whether a symptom rating changed.

Recommendations | Attention deficit hyperactivity disorder: diagnosis and management | Guidance | NICE

Read NICE’s monitoring recommendations to see what follow-up checks are for and why they continue after the initial trial.

In “1.8 Maintenance and monitoring,” read recommendations 1.8.1–1.8.5, beginning effectiveness and growth. Under “Cardiovascular,” read recommendations 1.8.9–1.8.12, from physical monitoring. Under “Sleep,” read recommendation 1.8.17, sleep changes. Focus on how each check could affect a treatment decision.

Medication can therefore sit alongside the supports from earlier lessons. A medicine might make it easier to stay with an assignment, while clear task steps help the person know where to start. If both are used, the useful outcome is improved functioning with acceptable adverse effects—not proof that one approach alone explains the difficulty.



Key takeaways

Stimulant and non-stimulant medicines can reduce ADHD symptoms, but their timing, benefits, and adverse effects differ. Choice depends on age, individual health and preferences, the activities treatment is meant to improve, and what happens during a monitored trial. Prescribing begins with a safety assessment and continues with review of symptoms, everyday functioning, and tolerability; medication response is not a diagnostic test.

The next lesson turns from treatment choices to claims about ADHD interventions: how to check the evidence, separate symptom change from functional benefit, and avoid overgeneralizing from one person’s experience.